We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Kiniksa Pharmaceuticals International Plc (KNSA) USD0.000273235 Class A

Sell:$20.55 Buy:$20.59 Change: $0.1 (0.49%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$20.55
Buy:$20.59
Change: $0.1 (0.49%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$20.55
Buy:$20.59
Change: $0.1 (0.49%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.

Contact details

Address:
23 Old Bond Street, Floor 3
LONDON
WIS 4PZ
United Kingdom
Telephone:
+ ()
Website:
https://www.kiniksa.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KNSA
ISIN:
GB00BRXB0C07
Market cap:
$1.45 billion
Shares in issue:
72.20 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Great Britain
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Sanjiv Patel
    Chairman of the Board, Chief Executive Officer
  • Mark Ragosa
    Chief Financial Officer, Senior Vice President
  • Eben Tessari
    Chief Operating Officer, Senior Vice President
  • Ross Moat
    Senior Vice President, Chief Commercial Officer
  • John Paolini
    Senior Vice President, Chief Medical Officer
  • Michael Megna
    Chief Accounting Officer, Group Vice President - Finance
  • Madelyn Zeylikman
    Vice President, Legal, to General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.